Pharmacokinetic‐Pharmacodynamic (Dipeptidyl Peptidase‐4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those with Renal Impairment, for the Once‐Weekly Administered Omarigliptin
Jain, Lokesh, Chain, Anne S.Y., Tatosian, Daniel A., Hing, Jeremy, Passarell, Julie A., Kauh, Eunkyung A., Lai, EsengJournal:
British Journal of Clinical Pharmacology
DOI:
10.1111/bcp.14103
Date:
August, 2019
File:
PDF, 433 KB
2019